Compare Novartis AG (NVS) vs Tilray Brands Inc (TLRY) Price & Performance

Novartis AGTrade

Tilray Brands IncTrade

Price performance (Past 24H)

Key statistics

Novartis AG vs Tilray Brands Inc — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Tilray Brands Inc trades at $4.24 (market cap $524.07M). The key difference: Novartis AG is far larger — about 553.8× Tilray Brands Inc's market cap, and Novartis AG pays a 3.17% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals.

	NVS	TLRY
Market Cap	$290.25B	$524.07M
Sector	Health	Health
52-Week High	$168.62	$21.00
52-Week Low	$113.50	$4.23
Enterprise Value	$330.27B	$621.22M
Dividend Yield	3.17%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novartis AG

Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.

The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.

Tilray Brands Inc

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NVS

Novartis Q2 earnings expected at $2.17 EPS, $14.07B revenue amid patent loss impact and key drug trials ahead.Gordon Thompson · 1 day agoNeutral New report details 1,230+ bioinformatics deals, revealing market trends and deal structures through 2026Researchandmarkets.Com · 4 days agoNeutral FDA approves Fabhalta as first drug to significantly slow kidney decline in IgAN patientsNovartis · 5 days agoBullish View details →

TLRY

Investors watch Tilray, Canopy Growth, and Village Farms for cannabis growth amid regulatory shifts in July 2026MarijuanaStocks · 13 hours agoBullish BrewDog and Tilray launch £1M bar tab for football fans in UK and Ireland from July to September 2026GlobeNewsWire · 4 days agoBullish View details →

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

About Tilray Brands Inc

Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.